1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,560 | 2,760 | 22:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023 | - | HKEx | ||
| Mo | WUXI XDC (02268): ANNUAL REPORT 2023 | 1 | HKEx | ||
| Fr | WUXI XDC (02268): REVISION OF ANNUAL CAPS FOR RAW MATERIALS PROCUREMENT SERVICES AGREEMENT | - | HKEx | ||
| 18.04. | M Stanley Cuts WUXI XDC (02268.HK) TP to $39, Rating Overweight | 1 | AASTOCKS | ||
| 25.03. | WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones | 68 | PR Newswire | Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022
Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022
Total number of integrated... ► Artikel lesen | |
| 25.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 | 1 | HKEx | ||
| 13.03. | WUXI XDC (02268): NOTICE OF BOARD MEETING | 2 | HKEx | ||
| 07.03. | WUXI XDC (02268): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 2 | HKEx | ||
| 09.02. | WUXI XDC (02268): EXCEEDED ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS | 3 | HKEx | ||
| 01.02. | FAST NEWS: WuXi XDC's profit surges on growth in ADC market | 3 | Bamboo Works | ||
| 01.02. | China's WuXi XDC jumps most in 9 weeks on robust results forecast | 1 | Reuters | ||
| 31.01. | WUXI XDC (02268): POSITIVE PROFIT ALERT AND BUSINESS UPDATE | 1 | HKEx | ||
| 29.01. | WUXI XDC (02268): VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE AND TRADING VOLUME MOVEMENTS | 1 | HKEx | ||
| 25.01. | Celltrion Partners with China's WuXi XDC for Joint Development of ADC Therapeutics | 6 | BusinessKorea | ||
| 24.01. | WuXi XDC, Celltrion Ink MOU for ADC Services | 1 | Contract Pharma | ||
| 24.01. | WuXi XDC, hot off $520M IPO, inks antibody-drug conjugate deal with Celltrion | 2 | FiercePharma | ||
| 24.01. | Celltrion, WuXi XDC to develop new antibody-drug conjugates | - | Korea Economic Daily | ||
| 24.01. | WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs) | 1.334 | PR Newswire | SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the... ► Artikel lesen | |
| 03.01. | WuXi CRDMO spinoff WuXi XDC inks partnership with IntoCell | 2 | FierceBiotech | ||
| 03.01. | WuXi XDC, IntoCell partner for drug-linker technology and CRDMO services | 1 | Pharmaceutical Business Review |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,080 | -0,17 % | Minimale Kursveränderung bei Qiagen NV-Aktie (38,75 €) | CODE Der jüngste Kurs betrug 38,75 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Qiagen NV-Aktie. Die Aktie weist aktuell nur einen minimalen Kursabschlag von 0,40 Prozent auf.... ► Artikel lesen | |
| MORPHOSYS | 66,20 | +0,84 % | ÜBERNAHME-FIEBER bei Biotech-Aktien! Evotec, Bayer, Vidac Pharma - wer folgt auf Morphosys? | Im Biotech-Sektor herrscht Übernahme-Fieber. Zuletzt hat Genmab den Kauf von ProfoundBio, das US-Biotech-Unternehmen entwickelt Medikamente gegen Eierstock- und Gebärmutterschleimhautkrebs, für 1,8... ► Artikel lesen | |
| EVOTEC | 9,740 | +1,19 % | Bayer, Evotec Partner to Advance Precision Cardiology Therapies? | ||
| HARMONY BIOSCIENCES | 30,910 | +5,68 % | Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy | WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half... ► Artikel lesen | |
| NUVALENT | 68,88 | +1,37 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,220 | -3,76 % | Expert Ratings For Beam Therapeutics | ||
| DAY ONE BIOPHARMACEUTICALS | 17,100 | +3,76 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| CABALETTA BIO | 10,645 | +1,57 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 25,570 | -3,98 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| BIONTECH | 83,65 | -0,24 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für das Biotechnologieunternehmen Biontech in einem Ausblick auf den Quartalsbericht mit einem Kursziel von 95 US-Dollar auf... ► Artikel lesen | |
| JANUX THERAPEUTICS | 57,04 | +1,71 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| 4D MOLECULAR THERAPEUTICS | 23,930 | -1,32 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,670 | +0,47 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| ARVINAS | 31,790 | -0,34 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,820 | -4,63 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,520 Euro und damit +0,80 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
